Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 28 articles: HTML format

Single Articles

April 2025
1. SMELIK M, Diaz-Roncero Gonzalez D, An X, Heer R, et al
   Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer.
   Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-25-0269.
   PubMed     Abstract available
   
   
   
2. CRUZ-HERNANDEZ CD, Smith B, Billet S, Thiruvalluvan M, et al
   A Cyanobacteria-derived RNA aptamer resensitizes prostate cancer to hormone therapy.
   Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-24-4039.
   PubMed     Abstract available
   
   
   February 2025
3. ZHAO Y, Ramesh N, Xu P, Sei E, et al
   Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer During Serial Therapy.
   Cancer Res. 2025 Feb 24. doi: 10.1158/0008-5472.CAN-24-1943.
   PubMed     Abstract available
   
   
   
4. ZHANG C, Ding J, Lim KS, Zhou W, et al
   JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer.
   Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-23-2796.
   PubMed     Abstract available
   
   
   December 2024
5. SIPOLA J, Munzur AD, Kwan EM, Seo CCY, et al
   Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer.
   Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2052.
   PubMed     Abstract available
   
   
   November 2024
6. BAE TH, Sung KW, Pham TM, Najy AJ, et al
   An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.
   Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-0591.
   PubMed     Abstract available
   
   
   
7. MCQUILLEN CN, Brady NJ
   ASCL1 Drives the Development of Neuroendocrine Prostate Cancer.
   Cancer Res. 2024;84:3499-3501.
   PubMed     Abstract available
   
   
   October 2024
8. ZHANG L, Troccoli CI, Mateo-Victoriano B, Misiara Lincheta L, et al
   Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
   Cancer Res. 2024 Oct 10. doi: 10.1158/0008-5472.CAN-24-0133.
   PubMed     Abstract available
   
   
   September 2024
9. RODARTE KE, Nir Heyman S, Guo L, Flores L, et al
   Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.
   Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-1388.
   PubMed     Abstract available
   
   
   August 2024
10. SONG H, Lu T, Han D, Zhang J, et al
    YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.
    Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-24-0932.
    PubMed     Abstract available
    
    
    
11. NING S, Armstrong CM, Xing E, Leslie AR, et al
    LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer.
    Cancer Res. 2024 Aug 1. doi: 10.1158/0008-5472.CAN-24-0440.
    PubMed     Abstract available
    
    
    July 2024
12. SHRESTHA R, Chesner LN, Zhang M, Zhou S, et al
    An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
    Cancer Res. 2024 Jul 11. doi: 10.1158/0008-5472.CAN-24-0890.
    PubMed     Abstract available
    
    
    
13. YOO YA, Quan S, Yang W, Guo Q, et al
    Asparagine Dependency is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Jul 3. doi: 10.1158/0008-5472.CAN-23-2910.
    PubMed     Abstract available
    
    
    June 2024
14. ZHANG W, Maeser D, Lee A, Huang Y, et al
    Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.
    Cancer Res. 2024;84:2021-2033.
    PubMed     Abstract available
    
    
    
15. LI W, Guo F, Zeng R, Liang H, et al
    CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer.
    Cancer Res. 2024 Jun 11. doi: 10.1158/0008-5472.CAN-23-3704.
    PubMed     Abstract available
    
    
    
16. BOUFAIED N, Chetta P, Hallal T, Cacciatore S, et al
    Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.
    Cancer Res. 2024;84:1834-1855.
    PubMed     Abstract available
    
    
    
17. FRIGO DE
    Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment.
    Cancer Res. 2024;84:1742-1744.
    PubMed     Abstract available
    
    
    
18. GALLAGHER K, Strobl MAR, Park DS, Spoendlin FC, et al
    Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy.
    Cancer Res. 2024;84:1929-1941.
    PubMed     Abstract available
    
    
    April 2024
19. SHRESTHA RK, Nassar ZD, Hanson AR, Iggo R, et al
    ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis.
    Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-1489.
    PubMed     Abstract available
    
    
    
20. CUNNINGHAM M, Schiewer MJ
    PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-3458.
    PubMed     Abstract available
    
    
    
21. MURPHY S, Rahmy S, Gan D, Liu G, et al
    Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.
    Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742.
    PubMed     Abstract available
    
    
    March 2024
22. SHU F, Liu H, Chen X, Liu Y, et al
    m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB.
    Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
    PubMed     Abstract available
    
    
    January 2024
23. ZHAO J, Xu N, Zhu S, Nie L, et al
    Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
    Cancer Res. 2024;84:154-167.
    PubMed     Abstract available
    
    
    December 2023
24. MISHRA R, Blinka S, Hsieh AC
    Citron Kinase Is a Druggable Target in Treatment-Resistant Prostate Cancer.
    Cancer Res. 2023;83:4008-4009.
    PubMed     Abstract available
    
    
    
25. AWAD D, Cao PHA, Pulliam TL, Spradlin M, et al
    Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-0555.
    PubMed     Abstract available
    
    
    October 2023
26. RAWAT C, Ben-Salem S, Singh N, Chauhan G, et al
    Prostate cancer progression relies on the mitotic kinase citron kinase.
    Cancer Res. 2023 Oct 6. doi: 10.1158/0008-5472.CAN-23-0883.
    PubMed     Abstract available
    
    
    September 2023
27. LI Z, Ning K, Zhao D, Zhou Z, et al
    Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling.
    Cancer Res. 2023 Sep 7. doi: 10.1158/0008-5472.CAN-23-0308.
    PubMed     Abstract available
    
    
    
28. NYQUIST MD, Coleman IM, Lucas JM, Li D, et al
    Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
    Cancer Res. 2023;83:2938-2951.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.